Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Contributor

Mark Vezina

Mark Vézina is the scientific director of the Ocular and Neuroscience Department at Charles River’s preclinical site in Montreal. Mark is an active member of the Ocular Toxicology Specialty Section of the Society of Toxicology (past president) and a regular contributor to the Ocular Research Group on Linked-In.

No contributions

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »